Your browser doesn't support javascript.
loading
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
Klein, Brad C; Miceli, Rosa; Severt, Lawrence; McAllister, Peter; Mechtler, Laszlo; McVige, Jennifer; Diamond, Merle; Marmura, Michael J; Guo, Hua; Finnegan, Michelle; Trugman, Joel M.
Affiliation
  • Klein BC; Abington Neurological Associates, Ltd., Abington, PA, USA.
  • Miceli R; AbbVie Inc., Madison, NJ, USA.
  • Severt L; AbbVie Inc., Madison, NJ, USA.
  • McAllister P; New England Institute for Neurology & Headache, Stamford, CT, USA.
  • Mechtler L; DENT Neurologic Institute, Amherst, NY, USA.
  • McVige J; DENT Neurologic Institute, Amherst, NY, USA.
  • Diamond M; Diamond Headache Clinic, Chicago, IL, USA.
  • Marmura MJ; Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Guo H; AbbVie Inc., Madison, NJ, USA.
  • Finnegan M; AbbVie Inc., Madison, NJ, USA.
  • Trugman JM; AbbVie Inc., Madison, NJ, USA.
Cephalalgia ; 43(1): 3331024221128250, 2023 01.
Article in En | MEDLINE | ID: mdl-36620892
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Migraine Disorders Type of study: Clinical_trials Limits: Humans Language: En Journal: Cephalalgia Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Migraine Disorders Type of study: Clinical_trials Limits: Humans Language: En Journal: Cephalalgia Year: 2023 Document type: Article Affiliation country: Country of publication: